Harmony Biosciences Holdings Stock Today
| HRMY Stock | USD 33.23 0.44 1.34% |
Performance0 of 100
| Odds Of DistressLess than 3
|
Harmony Biosciences is trading at 33.23 as of the 21st of November 2024; that is 1.34 percent up since the beginning of the trading day. The stock's open price was 32.79. Harmony Biosciences has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Harmony Biosciences Holdings are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of October 2024 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of August 2020 | Category Healthcare | Classification Health Care |
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania. The company has 57.03 M outstanding shares of which 6.06 M shares are currently shorted by private and institutional investors with about 6.8 trading days to cover. More on Harmony Biosciences Holdings
Moving together with Harmony Stock
Moving against Harmony Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Harmony Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Jeffrey MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsHarmony Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Harmony Biosciences' financial leverage. It provides some insight into what part of Harmony Biosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Harmony Biosciences Holdings (HRMY) is traded on NASDAQ Exchange in USA. It is located in 630 West Germantown Pike, Plymouth Meeting, PA, United States, 19462 and employs 246 people. Harmony Biosciences is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.87 B. Harmony Biosciences conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 57.03 M outstanding shares of which 6.06 M shares are currently shorted by private and institutional investors with about 6.8 trading days to cover.
Harmony Biosciences Holdings currently holds about 254.17 M in cash with 219.39 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.3.
Check Harmony Biosciences Probability Of Bankruptcy
Ownership AllocationHarmony Biosciences Holdings has a total of 57.03 Million outstanding shares. The majority of Harmony Biosciences outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Harmony Biosciences to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Harmony Biosciences Holdings. Please pay attention to any change in the institutional holdings of Harmony Biosciences as this could imply that something significant has changed or is about to change at the company. Also note that almost two million five hundred thirty-two thousand one hundred ninety invesors are currently shorting Harmony Biosciences expressing very little confidence in its future performance.
Check Harmony Ownership Details
Harmony Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Lsv Asset Management | 2024-09-30 | 772.2 K | |
| Geode Capital Management, Llc | 2024-06-30 | 748.7 K | |
| Citadel Advisors Llc | 2024-06-30 | 684.3 K | |
| Massachusetts Financial Services Company | 2024-09-30 | 660.4 K | |
| Federated Hermes Inc | 2024-09-30 | 542.1 K | |
| Renaissance Technologies Corp | 2024-09-30 | 492.6 K | |
| Goldman Sachs Group Inc | 2024-06-30 | 455.4 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 371.4 K | |
| Voloridge Investment Management, Llc | 2024-06-30 | 335.4 K | |
| Valor Management Llc | 2024-09-30 | 11.2 M | |
| Blackrock Inc | 2024-06-30 | 5.8 M |
Harmony Biosciences Historical Income Statement
Harmony Stock Against Markets
Harmony Biosciences Corporate Management
| Brennan Doyle | VP Relations | Profile | |
| Audrey Murphy | Head Resources | Profile | |
| David Bradshaw | Head Operations | Profile | |
| Cate McCanless | Head Policy | Profile | |
| MBA JD | Executive Officer | Profile | |
| Audrey SPHR | Head Resources | Profile | |
| Jeffrey Aronin | Founder Chairman | Profile |
Additional Tools for Harmony Stock Analysis
When running Harmony Biosciences' price analysis, check to measure Harmony Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harmony Biosciences is operating at the current time. Most of Harmony Biosciences' value examination focuses on studying past and present price action to predict the probability of Harmony Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harmony Biosciences' price. Additionally, you may evaluate how the addition of Harmony Biosciences to your portfolios can decrease your overall portfolio volatility.